PMID- 15625124
OWN - NLM
STAT- MEDLINE
DCOM- 20050609
LR  - 20171116
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 23
IP  - 1
DP  - 2005
TI  - Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral 
      blood from cancer patients.
PG  - 74-81
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that are integral to 
      the initiation of T-cell immunity. Two cell types can be used as a source for 
      generating DCs: monocytes and CD34(+) stem cells. Despite many investigations 
      characterizing DCs, none have performed a direct paired comparison of monocyte 
      and stem cell-derived DCs. Therefore, it is unclear whether one cell source has 
      particular advantages over the other, or whether inherent differences exist 
      between the two populations. We undertook the following study to determine if 
      there were any differences in DCs generated from monocytes or CD34(+) cells from 
      mobilized peripheral blood. DCs were generated by culturing the adherent cells 
      (monocytes) in interleukin-4 and GM-CSF for 7 days, or by culturing nonadherent 
      cells (CD34(+)) in the presence of GM-CSF and tumor necrosis factor alpha for 14 
      days. The resulting DCs were compared morphologically, phenotypically, 
      functionally, and by yield. We could generate morphologically and phenotypically 
      similar DCs. Differences were encountered when expression levels of some cell 
      surface markers were examined (CD86, HLA-DR). There was no difference in how the 
      DCs performed in a mixed lymphocyte reaction (p = .3). Further, no statistical 
      difference was discovered when we examined cellular (DC) yield (p = .1); however, 
      there was a significant difference when yield was normalized to the starting 
      number of monocytes or CD34(+) cells (p = .016). Together, these data demonstrate 
      that differences do exist between monocyte-derived DCs and CD34-derived DCs from 
      the same cellular product (apheresis) from the same individual.
FAU - Syme, Rachel
AU  - Syme R
AD  - Clinical Research Program, Department of Oncology, Tom Baker Cancer Centre, 1331 
      29th Street NW, Calgary, AB, T2N 4N2, Canada. rachelsy@cancerboard.ab.ca
FAU - Bajwa, Rubinder
AU  - Bajwa R
FAU - Robertson, Laurie
AU  - Robertson L
FAU - Stewart, Doug
AU  - Stewart D
FAU - Gluck, Stefan
AU  - Gluck S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (Antigens, CD34)
RN  - 0 (Lipopolysaccharide Receptors)
SB  - IM
MH  - Antigens, CD34/*blood/immunology/metabolism
MH  - Blood Component Removal
MH  - Dendritic Cells/*cytology/immunology/metabolism
MH  - *Hematopoietic Stem Cell Mobilization
MH  - Humans
MH  - Lipopolysaccharide Receptors/blood/immunology/metabolism
MH  - Monocytes/*cytology/immunology
MH  - Neoplasms/*blood
MH  - Phenotype
EDAT- 2004/12/31 09:00
MHDA- 2005/06/10 09:00
CRDT- 2004/12/31 09:00
PHST- 2004/12/31 09:00 [pubmed]
PHST- 2005/06/10 09:00 [medline]
PHST- 2004/12/31 09:00 [entrez]
AID - 23/1/74 [pii]
AID - 10.1634/stemcells.2004-0070 [doi]
PST - ppublish
SO  - Stem Cells. 2005;23(1):74-81. doi: 10.1634/stemcells.2004-0070.